Close

Research Insight

FDA approves Amgen’s BLA for high cholesterol treatment evolocumab

Amgen has received approval for review from US Food and Drug Administration (FDA) for its evolocumab to treat high cholesterol. The...

Takeda and GE Healthcare partner to develop therapeutic drugs for liver diseases

Japan-based Takeda Pharmaceutical has signed an alliance agreement with GE Healthcare for research and development of hepatic fibrosis. Hepatic fibrosis is...

ex scientia Ltd. Partners with Sunovion Pharmaceuticals Inc. to Research New Medicines for Psychiatric Disorders ex scientia Ltd.

exscientia Ltd. the polypharmacology driven drug discovery company announced today that they have signed an agreement with Sunovion Pharmaceuticals Inc. to collaborate...

AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approvalAstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approval

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients...

Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B disease

US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease...

Hikma to market Eisai’s epilepsy treatment Fycompa in Middle East

UK-based Hikma Pharmaceuticals has partnered with Eisai to distribute first-class epilepsy treatment Fycompa (perampanel) in the Middle East. Eisai ...

Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infection

Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read